ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-B7-H7/Anti-CD3 Bispecific Antibody NPX372

Its studies are mostly in Neoplasm Metastasis, led by NextPoint Therapeutics.

Furthest: phase 1, since Mar 30, 20261 company-led study, 1 open or runningNext primary completion: Apr 1, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
NextPoint Therapeutics11 open or runningphase 1since Mar 30, 2026Mar 30, 2026Apr 1, 2027phase 1 · NCT07563829

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 30, 2026First study: phase 1 study in Neoplasm MetastasisFirst studyNCT07563829 · 81 planned · United States

Ahead

  1. Apr 1, 2027Primary completion: phase 1 study in Neoplasm MetastasisNCT07563829

TargetBeta

CD3E →HHLA2 →read by rule
“An immunoglobulin G (IgG)-like bispecific T-cell engaging antibody directed against both HERV-H LTR-associating protein 2 (HHLA2; HHLA-2; B7 homolog 7; B7-H7) and T-cell surface antigen CD3, ”NCIt, by rule

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07563829Neoplasm Metastasis · United States1RecruitingApr 1, 202781

How it is read

Names in the registry

  • “NPX372”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.